David Gruben
Pfizer (United States)(US)
Publications by Year
Research Areas
Rheumatoid Arthritis Research and Therapies, Autoimmune and Inflammatory Disorders Research, Spondyloarthritis Studies and Treatments, Chronic Lymphocytic Leukemia Research, Inflammatory Bowel Disease
Most-Cited Works
- → Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis(2012)1,013 cited
- → Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis(2012)931 cited
- → Tofacitinib versus Methotrexate in Rheumatoid Arthritis(2014)765 cited
- → Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial(2013)715 cited
- → Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study(2013)578 cited
- → The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo(2009)542 cited
- → Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis(2013)445 cited
- → Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs(2011)376 cited
- → A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone(2011)344 cited
- → Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies(2014)302 cited